Preliminary prediction QSDH drug formulary can regulate the PI3K/AKT signaling pathway through quercetin, epigallocatechin-3-gallate, luteolin, wogonin, kaempferol, fisetin, and other active ingredients, acting on AKT1 target protein to inhibit inflammation, immune function, and cell metabolism, to achieve the purpose of treating MG. Here, AKT1 is linked to myasthenia gravis.